Thank you very much Louis, I’m glad to be here and to have the chance to tell you and your readers about the unique investment opportunity that Canntab represents.
We are the only company that we are aware of that is producing a cannabis hard pill. Given that most medical professionals believe that you don’t really have a medical solution until you have a hard pill, it’s difficult to believe that this isn’t a more competitive space. But, there is an explanation, it’s incredibly difficult to turn cannabis extract into a hard pill because the initial granulation process takes a great deal of time to develop. We should know, it’s taken us years to perfect this process and that is why we have patents pending in Canada and the United States that cover the full range of processes we utilize for not only the granulation but also for our specific timed-release formulations. This is our sustainable competitive advantage.
Even more importantly, with our partner FSD Pharma recently receiving their sales for medical license, the door has been opened for us to begin white labeling for Canadian and International organizations, while also developing our own branded products to be distributed through networks that we have already cultivated here in Canada as well as Mexico and Australia.
Jeff, I cannot thank you enough for this interview today and to introduce both yourself and Canntab Therapeutics Inc (“PILL”) to our subscribers.
Before we get into the details, let’s start with the end in mind. Can you give me an executive summary explaining why investors should consider adding Canntab to their portfolio?
89